Kenneth L. Davis

Kenneth L. Davis, MD
Medical career
Institutions	Mount Sinai Health System

Kenneth L. Davis is an American author and medical researcher who developed the Alzheimer's Disease Assessment Scale, the most widely used tool to test the efficacy of treatments for Alzheimer's Disease designed specifically to evaluate the severity of cognitive and noncognitive behavioral dysfunctions characteristic to persons with Alzheimer's disease.

His paper, "Dopamine in schizophrenia—a review and reconceptualization" (American Journal of Psychiatry, 148-11: 1474-86, November 1991) is the third most-cited paper on schizophrenia research in its decade.

He is currently the President and Chief Executive Officer of the Mount Sinai Health System in New York City.

Davis participated in breakthrough proof-of-concept studies and clinical trials of cholinesterase inhibitors. These trials (the first multicenter ones for cholinesterase inhibitors) established efficacy and ultimately led the first four of the five FDA-approved compounds for treating the symptoms of Alzheimer's: tacrine, rivastigmine, galantamine, donepezil and memantine

In 1978, Davis, together with Richard Mohs, conducted the first well-controlled study of a drug that was shown able to improve the storage and retrieval functions of long-term memory in humans.

...
Wikipedia